title: Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation.
abstract: Persistent diarrhea is commonly observed after solid organ transplantation (SOT). A few cases of mycophenolate mofetil (MMF)-induced duodenal villous atrophy (DVA) have been previously reported in kidney-transplant patients with chronic diarrhea. Herein, we report on the incidence and characteristics of DVA in SOT patients with chronic diarrhea. One hundred thirty-two SOT patients with chronic diarrhea underwent an oesophago-gastroduodenoscopy (OGD) and a duodenal biopsy after classical causes of diarrhea have been ruled out. DVA was diagnosed in 21 patients (15.9%). It was attributed to mycophenolic acid (MPA) therapy in 18 patients (85.7%) (MMF [n = 14] and enteric-coated mycophenolate sodium [n = 4]). MPA withdrawal or dose reduction resulted in diarrhea cessation. The incidence of DVA was significantly higher in patients with chronic diarrhea receiving MPA compared to those who did not (24.6% vs. 5.1%, p = 0.003). DVA was attributed to a Giardia lamblia parasitic infection in two patients (9.5%) and the remaining case was attributed to azathioprine. In these three patients, diarrhea ceased after metronidazole therapy or azathioprine dose reduction. In conclusion, DVA is a frequent cause of chronic diarrhea in SOT recipients. MPA therapy is the most frequent cause of DVA. An OGD should be proposed to all transplant recipients who present with persistent diarrhea.
authors.affiliation: Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: H
authors.initials: H
authors.lastname: Weclawiak
authors.forename: A
authors.initials: A
authors.lastname: Ould-Mohamed
authors.forename: B
authors.initials: B
authors.lastname: Bournet
authors.forename: C
authors.initials: C
authors.lastname: Guilbeau-Frugier
authors.forename: F
authors.initials: F
authors.lastname: Fortenfant
authors.forename: F
authors.initials: F
authors.lastname: Muscari
authors.forename: F
authors.initials: F
authors.lastname: Sallusto
authors.forename: C
authors.initials: C
authors.lastname: Dambrin
authors.forename: L
authors.initials: L
authors.lastname: Esposito
authors.forename: J
authors.initials: J
authors.lastname: Guitard
authors.forename: M
authors.initials: M
authors.lastname: Abbal
authors.forename: L
authors.initials: L
authors.lastname: Rostaing
authors.forename: N
authors.initials: N
authors.lastname: Kamar
mesh_terms: D000328:Adult; D000368:Aged; D001284:Atrophy / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology*; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology*; D004386:Duodenum / Q000187:drug effects / Q000473:pathology*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D016377:Organ Transplantation / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid